Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHPA on third class of drugs

This article was originally published in The Tan Sheet

Executive Summary

Two-class system of Rx and OTC drug regulation is a "time-tested system that provides consumers with convenient, cost-effective and safe treatment options," trade group maintains in 1May 27 statement reaffirming its opposition to "third class, or so-called transition class" of drugs. 2"The Tan Sheet" May 26, 2003 (p. 5) suggested CHPA was re-assessing its long-standing opposition to the idea of a third class...
Advertisement

Related Content

Behind-The-Counter Drug Class “On The Table” At CHPA
Behind-The-Counter Drug Class “On The Table” At CHPA

Topics

Advertisement
UsernamePublicRestriction

Register

PS095522

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel